Documentdetail
ID kaart

oai:pubmedcentral.nih.gov:1086...

Onderwerp
Research
Auteur
Adatia, Adil Moolji, Jalal Satia, Imran
Langue
en
Editor

BioMed Central

Categorie

Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology

Jaar

2024

vermelding datum

25-03-2024

Trefwoorden
increased hospitalization exacerbations
Metriek

Beschrijving

BACKGROUND: Asthma is a common respiratory illness affecting 2.8 million Canadians, including 9.7% of Albertans.

Prior studies showed a substantial decrease in ED visits for asthma in the decade preceding 2010, followed by a stabilization.

This was attributed to improvements in the pharmacologic and non-pharmacologic treatments for asthma during that period followed by a balance between epidemiologic drivers and protective factors in the population.

METHODS: We assessed whether this trend continued in Alberta from 2010 to 2022 using population level data for the volume of daily ED visits, acuity of asthma exacerbations in the ED, and hospitalization rate.

RESULTS: The mean number of ED visits decreased from 4.5 to 2.2 per million persons per day, but the acuity of exacerbations and the proportion requiring hospitalization increased.

The number of patients presenting with the highest level of acuity increased by over 300%, and the percentage of patients requiring hospitalization increased from 6.8 to 11.3%.

CONCLUSION: Total ED visits for asthma exacerbations continues to decline in Alberta.

The reasons for an increase in more severe exacerbations requires further attention.

SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13223-024-00872-0.

Adatia, Adil,Moolji, Jalal,Satia, Imran, 2024, Acuity of asthma exacerbations in Alberta, Canada is increasing: a population-based study, BioMed Central

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw